171 related articles for article (PubMed ID: 21816372)
1. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?
Thomas X; Chelghoum Y; Cannas G; Elhamri M; Labussière H; Tigaud I; Ducastelle S; Nicolini F; Dumontet C; Michallet M
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):342-9. PubMed ID: 21816372
[TBL] [Abstract][Full Text] [Related]
2. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
6. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
8. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
9. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
10. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
[TBL] [Abstract][Full Text] [Related]
11. The benefit of induction chemotherapy in patients age > or = 75 years.
Vey N; Coso D; Bardou VJ; Stoppa AM; Braud AC; Bouabdallah R; Sainty D; Mozziconacci MJ; Lafage M; Damaj G; Blaise D; Gastaut JA; Maraninchi D
Cancer; 2004 Jul; 101(2):325-31. PubMed ID: 15241830
[TBL] [Abstract][Full Text] [Related]
12. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
[TBL] [Abstract][Full Text] [Related]
13. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
15. The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.
Tasaki T; Yamauchi T; Matsuda Y; Takai M; Ookura M; Lee S; Tai K; Ikegaya S; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5631-6. PubMed ID: 25275066
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
[TBL] [Abstract][Full Text] [Related]
17. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
[TBL] [Abstract][Full Text] [Related]
19. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
[TBL] [Abstract][Full Text] [Related]
20. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
Etienne A; Esterni B; Charbonnier A; Mozziconacci MJ; Arnoulet C; Coso D; Puig B; Gastaut JA; Maraninchi D; Vey N
Cancer; 2007 Apr; 109(7):1376-83. PubMed ID: 17326052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]